

SUBJECT: 2021-2022 Universal Influenza Immunization Program – Vaccine Distribution
Date: September 17, 2021
Pages: 3 (plus attached weekly vaccine order form)
To: Physicians, Hospitals, Long-Term Care and Prequalified Retirement Homes
From: Vaccine and Medication Administrators

Wellington-Dufferin-Guelph Public Health (WDGPH) will be distributing our first provincial allotment of Influenza vaccine the week of September 27, 2021, with long term care homes, retirement homes and hospitals prioritized. Primary care providers will follow.

Please ensure your vaccine supply can accommodate the needs of your facility/practice until we receive our second shipment - the week of October 18, 2021; allocate your doses accordingly.

Influenza vaccination should be offered to all patients over the age of six months. Health care providers can begin immunizing patients for influenza as soon as vaccine is received.

Vaccine Viral Strain Components for the 2021-2022 Season

Quadrivalent Inactivated influenza Vaccine (IIV4-SD)	High-dose Trivalent Inactivated Influenza Vaccine (IIV3-HD)
<p>Egg-based Vaccines:</p> <ul style="list-style-type: none"> • an A/Victoria/2570/2019 (H1N1) pdm09-like virus; • an A/Cambodia/e0826360/2020 (H3N2)-like virus; • a B/Washington/02/2019 (B/Victoria lineage)-like virus; and • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus <p>Cell- or recombinant-based Vaccines:</p> <ul style="list-style-type: none"> • an A/Wisconsin/588/2019 (H1N1) pdm09-like virus; • an A/Cambodia/e0826360/2020 (H3N2)-like virus; • a B/Washington/02/2019 (B/Victoria lineage)-like virus; and • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus. 	<p>Egg-based Vaccines:</p> <ul style="list-style-type: none"> • an A/Victoria/2570/2019 (H1N1) pdm09-like virus; • an A/Cambodia/e0826360/2020 (H3N2)-like virus; and • a B/Washington/02/2019 (B/Victoria lineage)-like virus <p>Cell- or recombinant-based Vaccines</p> <ul style="list-style-type: none"> • an A/Wisconsin/588/2019 (H1N1) pdm09-like virus; • an A/Cambodia/e0826360/2020 (H3N2)-like virus; and • a B/Washington/02/2019 (B/Victoria lineage)-like virus

NOTE: When available, IIV-HD should be used over IIV-SD, given the burden of influenza A(H3N2) disease and the good evidence of better protection of IIV3-HD compared to IIV3-SD in adults 65 years of age and older. Based on a review of pre-authorization trials, IIV4-HD is non-inferior to IIV3-HD and is therefore expected to provide the same enhanced protection against A(H3N2) compared to standard dose IIV, including IIV4-SD. Although IIV-HD is expected to provide better protection against influenza A(H3N2) for adults 65 years of age or older, the benefit of providing this vaccine to all adults 65+ as opposed to any other influenza vaccine is not clear (NACI 2021-2022).

Available influenza vaccine distributed by the Ministry:

Product	New Product Abbreviation	Dosage	Packaging	Licensed Ages for Use
Flulaval Tetra	IIV4-SD (Quadrivalent inactivated influenza vaccine-standard dose)	0.5ml	Multi-dose vial 10 doses/vial	≥ 6 months of age
Fluzone Quadrivalent	IIV4-SD (Quadrivalent inactivated influenza vaccine-standard dose)	0.5ml	10 single dose prefilled syringes or Multi dose vial	≥ 6 months of age
Flucelvax Quad	IIV4-SD (Quadrivalent inactivated influenza vaccine-standard dose)	0.5ml	10 single dose prefilled syringes or Multi dose vial	≥ 2 years of age
Afluria® Tetra (Note: primarily distributed to pharmacies)	IIV4-SD (Quadrivalent inactivated influenza vaccine-standard dose)	0.5ml	10 single dose prefilled syringes	≥ 5 years of age
Fluzone High Dose	IIV4-HD (Quadrivalent inactivated influenza vaccine-high dose)	0.7ml	5 single dose prefilled syringes	≥65 years
Fluad®	IIV3 (Adjuvanted Trivalent Inactivated Vaccine)	0.5ml	10 single dose prefilled syringes	≥65 years

Important Notes:

Fluzone® High-Dose Quadrivalent is only authorized for those 65 years of age and older. Fluzone® Quadrivalent and Fluzone® High-Dose Quadrivalent are different products. Please use caution when administering Fluzone® products to ensure that the right vaccine is being administered to the right person.

Fluzone® High-Dose Quadrivalent and Fluad® will be available through primary care providers (e.g., physicians and nurse practitioners), participating pharmacies and retirement homes, LTCHs and hospitals.

FluMist® will not be publicly funded for the 2021/2022 influenza season.

Publicly funded influenza vaccines must be administered by a regulated health professional who is authorized under the Regulated Health Professions Act, 1991 to administer vaccines, or by a trained individual under a delegation made in accordance with the requirements set by the regulatory College of the regulated health professional.

Publicly funded vaccine may be administered to individuals who meet the eligibility criteria for the UIIP (i.e., individuals who are 6 months of age and older who live, work or study in Ontario) and without contraindications to the vaccine.

Trained pharmacists may only administer publicly funded influenza vaccine to individuals 2 years of age and older.

For more information, refer to contact or website:

WDGPH Vaccine and Medication Administrator: Wellington & Dufferin

Name/Title: Susanne Dunford

Contact: 519-822-2715 or 1-800-265-7293 ext. 2622 / www.wdgpUBLICHEALTH.ca

WDGPH Vaccine and Medication Administrator: Guelph

Name/Title: Lindsay Risch/Maya Hedican

Contact: 519-822-2715 or 1-800-265-7293 ext. 4170 / www.wdgpUBLICHEALTH.ca